Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2022

Open Access 01-12-2022 | osteosarcoma | Review

The emerging role of pyroptosis in pediatric cancers: from mechanism to therapy

Authors: Hua Wang, Xiaowen Zhou, Chenbei Li, Shuxiang Yan, Chengyao Feng, Jieyu He, Zhihong Li, Chao Tu

Published in: Journal of Hematology & Oncology | Issue 1/2022

Login to get access

Abstract

Pediatric cancers are the driving cause of death for children and adolescents. Due to safety requirements and considerations, treatment strategies and drugs for pediatric cancers have been so far scarcely studied. It is well known that tumor cells tend to progressively evade cell death pathways, which is known as apoptosis resistance, one of the hallmarks of cancer, dominating tumor drug resistance. Recently, treatments targeting nonapoptotic cell death have drawn great attention. Pyroptosis, a newly specialized form of cell death, acts as a critical physiological regulator in inflammatory reaction, cell development, tissue homeostasis and stress response. The action in different forms of pyroptosis is of great significance in the therapy of pediatric cancers. Pyroptosis could be induced and consequently modulate tumorigenesis, progression, and metastasis if treated with local or systemic therapies. However, excessive or uncontrolled cell death might lead to tissue damage, acute inflammation, or even cytokine release syndrome, which facilitates tumor progression or recurrence. Herein, we aimed to describe the molecular mechanisms of pyroptosis, to highlight and discuss the challenges and opportunities for activating pyroptosis pathways through various oncologic therapies in multiple pediatric neoplasms, including osteosarcoma, neuroblastoma, leukemia, lymphoma, and brain tumors.
Literature
1.
Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25(3):486–541.PubMedPubMedCentralCrossRef
2.
3.
4.
Deter RL, De Duve C. Influence of glucagon, an inducer of cellular autophagy, on some physical properties of rat liver lysosomes. J Cell Biol. 1967;33(2):437–49.PubMedPubMedCentralCrossRef
5.
6.
Friedlander AM. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J Biol Chem. 1986;261(16):7123–6.PubMedCrossRef
7.
Zheng M, Kanneganti TD. The regulation of the ZBP1-NLRP3 inflammasome and its implications in pyroptosis, apoptosis, and necroptosis (PANoptosis). Immunol Rev. 2020;297(1):26–38.PubMedPubMedCentralCrossRef
8.
Malireddi RKS, Kesavardhana S, Kanneganti TD. ZBP1 and TAK1: master regulators of NLRP3 inflammasome/pyroptosis, apoptosis, and necroptosis (PAN-optosis). Front Cell Infect Microbiol. 2019;9:406.PubMedPubMedCentralCrossRef
9.
Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S, et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol. 2000;1(6):489–95.PubMedCrossRef
10.
Yang WS, Stockwell BR. Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 2016;26(3):165–76.PubMedCrossRef
11.
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–72.PubMedPubMedCentralCrossRef
12.
13.
Tang D, Chen X, Kroemer G. Cuproptosis: a copper-triggered modality of mitochondrial cell death. Cell Res. 2022;32(5):417–8.PubMedCrossRef
14.
David KK, Andrabi SA, Dawson TM, Dawson VL. Parthanatos, a messenger of death. Front Biosci (Landmark Ed). 2009;14(3):1116–28.CrossRef
15.
Delettre C, Yuste VJ, Moubarak RS, Bras M, Lesbordes-Brion JC, Petres S, et al. AIFsh, a novel apoptosis-inducing factor (AIF) pro-apoptotic isoform with potential pathological relevance in human cancer. J Biol Chem. 2006;281(10):6413–27.PubMedCrossRef
16.
Liu J, Kuang F, Kang R, Tang D. Alkaliptosis: a new weapon for cancer therapy. Cancer Gene Ther. 2020;27(5):267–9.PubMedCrossRef
17.
Song X, Zhu S, Xie Y, Liu J, Sun L, Zeng D, et al. JTC801 induces pH-dependent death specifically in cancer cells and slows growth of tumors in mice. Gastroenterology. 2018;154(5):1480–93.PubMedCrossRef
18.
Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526(7575):660–5.PubMedCrossRef
19.
Zhao J, Jiang P, Guo S, Schrodi SJ, He D. Apoptosis, autophagy, NETosis, necroptosis, and pyroptosis mediated programmed cell death as targets for innovative therapy in rheumatoid arthritis. Front Immunol. 2021;12: 809806.PubMedPubMedCentralCrossRef
20.
Frank D, Vince JE. Pyroptosis versus necroptosis: similarities, differences, and crosstalk. Cell Death Differ. 2019;26(1):99–114.PubMedCrossRef
21.
22.
Gao Y, Volegova M, Nasholm N, Das S, Kwiatkowski N, Abraham BJ, et al. Synergistic anti-tumor effect of combining selective CDK7 and BRD4 inhibition in neuroblastoma. Front Oncol. 2021;11: 773186.PubMedCrossRef
23.
Zhang W, He L, Liu Z, Ren X, Qi L, Wan L, et al. Multifaceted functions and novel insight into the regulatory role of RNA N(6)-methyladenosine modification in musculoskeletal disorders. Front Cell Dev Biol. 2020;8:870.PubMedPubMedCentralCrossRef
24.
25.
Chen Y, Miao L, Lin H, Zhuo Z, He J. The role of m6A modification in pediatric cancer. Biochim Biophys Acta Rev Cancer. 2022;1877(2): 188691.PubMedCrossRef
26.
Force LM, Abdollahpour I, Advani SM, Agius D, Ahmadian E, Alahdab F, Alam T, Alebel A, Alipour V, Allen CA, Almasi-Hashiani A. The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017. Lancet Oncol. 2019;20(9):1211–25.CrossRef
27.
Barone A, Casey D, McKee AE, Reaman G. Cancer drugs approved for use in children: impact of legislative initiatives and future opportunities. Pediatr Blood Cancer. 2019;66(8): e27809.PubMedCrossRef
28.
Cerella C, Teiten MH, Radogna F, Dicato M, Diederich M. From nature to bedside: pro-survival and cell death mechanisms as therapeutic targets in cancer treatment. Biotechnol Adv. 2014;32(6):1111–22.PubMedCrossRef
29.
Shi J, Gao W, Shao F. Pyroptosis: gasdermin-mediated programmed necrotic cell death. Trends Biochem Sci. 2017;42(4):245–54.PubMedCrossRef
30.
31.
32.
Solinas G, Marchesi F, Garlanda C, Mantovani A, Allavena P. Inflammation-mediated promotion of invasion and metastasis. Cancer Metastasis Rev. 2010;29(2):243–8.PubMedCrossRef
33.
Ding Q, Zhang W, Cheng C, Mo F, Chen L, Peng G, et al. Dioscin inhibits the growth of human osteosarcoma by inducing G2/M-phase arrest, apoptosis, and GSDME-dependent cell death in vitro and in vivo. J Cell Physiol. 2020;235(3):2911–24.PubMedCrossRef
34.
Lin R, Wei H, Wang S, Huang Z, Chen H, Zhang S, et al. Gasdermin D expression and clinicopathologic outcome in primary osteosarcoma patients. Int J Clin Exp Pathol. 2020;13(12):3149–57.PubMedPubMedCentral
35.
Bu X, Liu J, Ding R, Li Z. Prognostic value of a pyroptosis-related long noncoding RNA signature associated with osteosarcoma microenvironment. J Oncol. 2021;2021:2182761.PubMedPubMedCentralCrossRef
36.
Zhang Y, He R, Lei X, Mao L, Jiang P, Ni C, et al. A novel pyroptosis-related signature for predicting prognosis and indicating immune microenvironment features in osteosarcoma. Front Genet. 2021;12: 780780.PubMedPubMedCentralCrossRef
37.
Kang X, Jiang L, Chen X, Wang X, Gu S, Wang J, et al. Exosomes derived from hypoxic bone marrow mesenchymal stem cells rescue OGD-induced injury in neural cells by suppressing NLRP3 inflammasome-mediated pyroptosis. Exp Cell Res. 2021;405(1): 112635.PubMedCrossRef
38.
Zhang J, Chen Y, He Q. Distinct characteristics of dasatinib-induced pyroptosis in gasdermin E-expressing human lung cancer A549 cells and neuroblastoma SH-SY5Y cells. Oncol Lett. 2020;20(1):145–54.PubMedPubMedCentralCrossRef
39.
Zhao MW, Yang P, Zhao LL. Chlorpyrifos activates cell pyroptosis and increases susceptibility on oxidative stress-induced toxicity by miR-181/SIRT1/PGC-1α/Nrf2 signaling pathway in human neuroblastoma SH-SY5Y cells: Implication for association between chlorpyrifos and Parkinson’s disease. Environ Toxicol. 2019;34(6):699–707.PubMedCrossRef
40.
41.
Zheng M, Karki R, Kancharana B, Berns H, Pruett-Miller SM, Kanneganti TD. Caspase-6 promotes activation of the caspase-11-NLRP3 inflammasome during gram-negative bacterial infections. J Biol Chem. 2021;297(6): 101379.PubMedPubMedCentralCrossRef
42.
43.
Xing Y, Zhao J, Zhou M, Jing S, Zhao X, Mao P, et al. The LPS induced pyroptosis exacerbates BMPR2 signaling deficiency to potentiate SLE-PAH. FASEB J. 2021;35(12): e22044.PubMedCrossRef
44.
Gao YL, Zhai JH, Chai YF. Recent advances in the molecular mechanisms underlying pyroptosis in sepsis. Mediat Inflamm. 2018;2018:5823823.CrossRef
45.
Hersh D, Monack DM, Smith MR, Ghori N, Falkow S, Zychlinsky A. The Salmonella invasin SipB induces macrophage apoptosis by binding to caspase-1. Proc Natl Acad Sci U S A. 1999;96(5):2396–401.PubMedPubMedCentralCrossRef
46.
Kijima M, Mizuta R. Histone H1 quantity determines the efficiencies of apoptotic DNA fragmentation and chromatin condensation. Biomed Res. 2019;40(1):51–6.PubMedCrossRef
47.
Xu YJ, Zheng L, Hu YW, Wang Q. Pyroptosis and its relationship to atherosclerosis. Clin Chim Acta. 2018;476:28–37.PubMedCrossRef
48.
Walker PR, Leblanc J, Smith B, Pandey S, Sikorska M. Detection of DNA fragmentation and endonucleases in apoptosis. Methods. 1999;17(4):329–38.PubMedCrossRef
49.
Chen X, Zeh HJ, Kang R, Kroemer G, Tang D. Cell death in pancreatic cancer: from pathogenesis to therapy. Nat Rev Gastroenterol Hepatol. 2021;18(11):804–23.PubMedCrossRef
50.
Wang Y, Peng J, Xie X, Zhang Z, Li M, Yang M. Gasdermin E-mediated programmed cell death: an unpaved path to tumor suppression. J Cancer. 2021;12(17):5241–8.PubMedPubMedCentralCrossRef
51.
Tonnus W, Belavgeni A, Beuschlein F, Eisenhofer G, Fassnacht M, Kroiss M, et al. The role of regulated necrosis in endocrine diseases. Nat Rev Endocrinol. 2021;17(8):497–510.PubMedPubMedCentralCrossRef
52.
53.
Wang Y, Kanneganti TD. From pyroptosis, apoptosis and necroptosis to PANoptosis: a mechanistic compendium of programmed cell death pathways. Comput Struct Biotechnol J. 2021;19:4641–57.PubMedPubMedCentralCrossRef
54.
55.
Jiang M, Qi L, Li L, Wu Y, Song D, Li Y. Caspase-8: a key protein of cross-talk signal way in “PANoptosis” in cancer. Int J Cancer. 2021;149(7):1408–20.PubMedCrossRef
56.
Qiu Y, Cao Y, Cao W, Jia Y, Lu N. The application of ferroptosis in diseases. Pharmacol Res. 2020;159: 104919.PubMedCrossRef
57.
Mao C, Liu X, Zhang Y, Lei G, Yan Y, Lee H, et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature. 2021;593(7860):586–90.PubMedPubMedCentralCrossRef
58.
Ubellacker JM, Tasdogan A, Ramesh V, Shen B, Mitchell EC, Martin-Sandoval MS, et al. Lymph protects metastasizing melanoma cells from ferroptosis. Nature. 2020;585(7823):113–8.PubMedPubMedCentralCrossRef
59.
Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375(6586):1254–61.PubMedPubMedCentralCrossRef
60.
Lin L, Zhang MX, Zhang L, Zhang D, Li C, Li YL. Autophagy, pyroptosis, and ferroptosis: new regulatory mechanisms for atherosclerosis. Front Cell Dev Biol. 2021;9: 809955.PubMedCrossRef
61.
D’Arcy MS. Cell death: a review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int. 2019;43(6):582–92.PubMedCrossRef
62.
Wang Y, Gao W, Shi X, Ding J, Liu W, He H, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017;547(7661):99–103.PubMedCrossRef
63.
Ball B, Zeidan A, Gore SD, Prebet T. Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings. Leuk Lymphoma. 2017;58(5):1022–36.PubMedCrossRef
64.
Zhang CC, Li CG, Wang YF, Xu LH, He XH, Zeng QZ, et al. Chemotherapeutic paclitaxel and cisplatin differentially induce pyroptosis in A549 lung cancer cells via caspase-3/GSDME activation. Apoptosis. 2019;24(3–4):312–25.PubMedCrossRef
65.
Yu J, Li S, Qi J, Chen Z, Wu Y, Guo J, et al. Cleavage of GSDME by caspase-3 determines lobaplatin-induced pyroptosis in colon cancer cells. Cell Death Dis. 2019;10(3):193.PubMedPubMedCentralCrossRef
66.
Yu P, Wang HY, Tian M, Li AX, Chen XS, Wang XL, et al. Eukaryotic elongation factor-2 kinase regulates the cross-talk between autophagy and pyroptosis in doxorubicin-treated human melanoma cells in vitro. Acta Pharmacol Sin. 2019;40(9):1237–44.PubMedPubMedCentralCrossRef
67.
Kong Y, Feng Z, Chen A, Qi Q, Han M, Wang S, et al. The natural flavonoid galangin elicits apoptosis, pyroptosis, and autophagy in glioblastoma. Front Oncol. 2019;9:942.PubMedPubMedCentralCrossRef
68.
Yue E, Tuguzbaeva G, Chen X, Qin Y, Li A, Sun X, et al. Anthocyanin is involved in the activation of pyroptosis in oral squamous cell carcinoma. Phytomedicine. 2019;56:286–94.PubMedCrossRef
69.
Fan D, Yang Z, Yuan Y, Wu QQ, Xu M, Jin YG, et al. Sesamin prevents apoptosis and inflammation after experimental myocardial infarction by JNK and NF-κB pathways. Food Funct. 2017;8(8):2875–85.PubMedCrossRef
70.
Zhang H, Liao X, Wu X, Shi C, Zhang Y, Yuan Y, et al. Iridium(III) complexes entrapped in liposomes trigger mitochondria-mediated apoptosis and GSDME-mediated pyroptosis. J Inorg Biochem. 2022;228: 111706.PubMedCrossRef
71.
Jiang Z, Yao L, Ma H, Xu P, Li Z, Guo M, et al. miRNA-214 inhibits cellular proliferation and migration in glioma cells targeting caspase 1 involved in pyroptosis. Oncol Res. 2017;25(6):1009–19.PubMedPubMedCentralCrossRef
72.
Lu Y, He W, Huang X, He Y, Gou X, Liu X, et al. Strategies to package recombinant Adeno-Associated Virus expressing the N-terminal gasdermin domain for tumor treatment. Nat Commun. 2021;12(1):7155.PubMedPubMedCentralCrossRef
73.
Erkes DA, Cai W, Sanchez IM, Purwin TJ, Rogers C, Field CO, et al. Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis. Cancer Discov. 2020;10(2):254–69.PubMedCrossRef
74.
Shi Z, Yuan S, Shi L, Li J, Ning G, Kong X, et al. Programmed cell death in spinal cord injury pathogenesis and therapy. Cell Prolif. 2021;54(3): e12992.PubMedPubMedCentralCrossRef
75.
Li Z, Liu W, Fu J, Cheng S, Xu Y, Wang Z, et al. Shigella evades pyroptosis by arginine ADP-riboxanation of caspase-11. Nature. 2021;599(7884):290–5.PubMedCrossRef
76.
77.
78.
79.
Liston A, Masters SL. Homeostasis-altering molecular processes as mechanisms of inflammasome activation. Nat Rev Immunol. 2017;17(3):208–14.PubMedCrossRef
80.
Jing W, Lo Pilato J, Kay C, Man SM. Activation mechanisms of inflammasomes by bacterial toxins. Cell Microbiol. 2021;23(4): e13309.PubMedCrossRef
81.
Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert D, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol. 2009;183(2):787–91.PubMedCrossRef
82.
Xing Y, Yao X, Li H, Xue G, Guo Q, Yang G, et al. Cutting edge: TRAF6 mediates TLR/IL-1R signaling-induced nontranscriptional priming of the NLRP3 inflammasome. J Immunol. 2017;199(5):1561–6.PubMedCrossRef
83.
Orlowski GM, Colbert JD, Sharma S, Bogyo M, Robertson SA, Rock KL. Multiple cathepsins promote pro-IL-1β synthesis and NLRP3-mediated IL-1β activation. J Immunol. 2015;195(4):1685–97.PubMedCrossRef
84.
85.
Lee GS, Subramanian N, Kim AI, Aksentijevich I, Goldbach-Mansky R, Sacks DB, et al. The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP. Nature. 2012;492(7427):123–7.PubMedPubMedCentralCrossRef
86.
Schmid-Burgk JL, Gaidt MM, Schmidt T, Ebert TS, Bartok E, Hornung V. Caspase-4 mediates non-canonical activation of the NLRP3 inflammasome in human myeloid cells. Eur J Immunol. 2015;45(10):2911–7.PubMedCrossRef
87.
Beckwith KS, Beckwith MS, Ullmann S, Sætra RS, Kim H, Marstad A, et al. Plasma membrane damage causes NLRP3 activation and pyroptosis during Mycobacterium tuberculosis infection. Nat Commun. 2020;11(1):2270.PubMedPubMedCentralCrossRef
88.
Baker PJ, Boucher D, Bierschenk D, Tebartz C, Whitney PG, D’Silva DB, et al. NLRP3 inflammasome activation downstream of cytoplasmic LPS recognition by both caspase-4 and caspase-5. Eur J Immunol. 2015;45(10):2918–26.PubMedCrossRef
89.
Rühl S, Broz P. Caspase-11 activates a canonical NLRP3 inflammasome by promoting K(+) efflux. Eur J Immunol. 2015;45(10):2927–36.PubMedCrossRef
90.
Yang D, He Y, Muñoz-Planillo R, Liu Q, Núñez G. Caspase-11 Requires the pannexin-1 channel and the purinergic P2X7 pore to mediate pyroptosis and endotoxic shock. Immunity. 2015;43(5):923–32.PubMedPubMedCentralCrossRef
91.
Orning P, Weng D, Starheim K, Ratner D, Best Z, Lee B, et al. Pathogen blockade of TAK1 triggers caspase-8-dependent cleavage of gasdermin D and cell death. Science. 2018;362(6418):1064–9.PubMedPubMedCentralCrossRef
92.
Hou J, Zhao R, Xia W, Chang CW, You Y, Hsu JM, et al. PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nat Cell Biol. 2020;22(10):1264–75.PubMedPubMedCentralCrossRef
93.
94.
95.
Zhang Z, Zhang Y, Xia S, Kong Q, Li S, Liu X, et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature. 2020;579(7799):415–20.PubMedPubMedCentralCrossRef
96.
97.
Wang J, Liu S, Shi J, Li J, Wang S, Liu H, et al. The role of miRNA in the diagnosis, prognosis, and treatment of osteosarcoma. Cancer Biother Radiopharm. 2019;34(10):605–13.PubMed
98.
Tu C, Yang K, Wan L, He J, Qi L, Wang W, et al. The crosstalk between lncRNAs and the Hippo signalling pathway in cancer progression. Cell Prolif. 2020;53(9): e12887.PubMedPubMedCentralCrossRef
99.
Kansara M, Teng MW, Smyth MJ, Thomas DM. Translational biology of osteosarcoma. Nat Rev Cancer. 2014;14(11):722–35.PubMedCrossRef
100.
Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33(27):3029–35.PubMedPubMedCentralCrossRef
101.
Bhattasali O, Vo AT, Roth M, Geller D, Randall RL, Gorlick R, et al. Variability in the reported management of pulmonary metastases in osteosarcoma. Cancer Med. 2015;4(4):523–31.PubMedPubMedCentralCrossRef
102.
Zhang W, Liu Z, Yang Z, Feng C, Zhou X, Tu C, et al. MTHFR polymorphism is associated with severe methotrexate-induced toxicity in osteosarcoma treatment. Front Oncol. 2021;11: 781386.PubMedPubMedCentralCrossRef
103.
Bai L, Wang S. Targeting apoptosis pathways for new cancer therapeutics. Annu Rev Med. 2014;65:139–55.PubMedCrossRef
104.
Zhang C, He J, Qi L, Wan L, Wang W, Tu C, et al. Diagnostic and prognostic significance of dysregulated expression of circular RNAs in osteosarcoma. Expert Rev Mol Diagn. 2021;21(2):235–44.PubMedCrossRef
105.
106.
Franceschini N, Lam SW, Cleton-Jansen AM, Bovée J. What’s new in bone forming tumours of the skeleton? Virchows Arch. 2020;476(1):147–57.PubMedCrossRef
107.
Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment—Where do we stand? A state of the art review. Cancer Treat Rev. 2014;40(4):523–32.PubMedCrossRef
108.
Tu C, He J, Qi L, Ren X, Zhang C, Duan Z, et al. Emerging landscape of circular RNAs as biomarkers and pivotal regulators in osteosarcoma. J Cell Physiol. 2020;235(12):9037–58.PubMedCrossRef
109.
Gao J, Qiu X, Xi G, Liu H, Zhang F, Lv T, et al. Downregulation of GSDMD attenuates tumor proliferation via the intrinsic mitochondrial apoptotic pathway and inhibition of EGFR/Akt signaling and predicts a good prognosis in non-small cell lung cancer. Oncol Rep. 2018;40(4):1971–84.PubMedPubMedCentral
110.
Peng J, Jiang H, Guo J, Huang J, Yuan Q, Xie J, et al. CD147 Expression is associated with tumor proliferation in bladder cancer via GSDMD. Biomed Res Int. 2020;2020:7638975.PubMedPubMedCentralCrossRef
111.
Yan H, Luo B, Wu X, Guan F, Yu X, Zhao L, et al. Cisplatin induces pyroptosis via activation of MEG3/NLRP3/caspase-1/GSDMD pathway in triple-negative breast cancer. Int J Biol Sci. 2021;17(10):2606–21.PubMedPubMedCentralCrossRef
112.
Tsubota S, Kadomatsu K. Origin and initiation mechanisms of neuroblastoma. Cell Tissue Res. 2018;372(2):211–21.PubMedCrossRef
113.
Swift CC, Eklund MJ, Kraveka JM, Alazraki AL. Updates in diagnosis, management, and treatment of neuroblastoma. Radiographics. 2018;38(2):566–80.PubMedCrossRef
114.
Whittle SB, Smith V, Doherty E, Zhao S, McCarty S, Zage PE. Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther. 2017;17(4):369–86.PubMedCrossRef
115.
Pfluger T, Piccardo A. Neuroblastoma: MIBG imaging and new tracers. Semin Nucl Med. 2017;47(2):143–57.PubMedCrossRef
116.
Gains JE, Bomanji JB, Fersht NL, Sullivan T, D’Souza D, Sullivan KP, et al. 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. J Nucl Med. 2011;52(7):1041–7.PubMedCrossRef
117.
Eleveld TF, Oldridge DA, Bernard V, Koster J, Colmet Daage L, Diskin SJ, et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet. 2015;47(8):864–71.PubMedPubMedCentralCrossRef
118.
Masuda Y, Futamura M, Kamino H, Nakamura Y, Kitamura N, Ohnishi S, et al. The potential role of DFNA5, a hearing impairment gene, in p53-mediated cellular response to DNA damage. J Hum Genet. 2006;51(8):652–64.PubMedCrossRef
119.
El-Deiry WS. The role of p53 in chemosensitivity and radiosensitivity. Oncogene. 2003;22(47):7486–95.PubMedCrossRef
120.
Chen L, Weng B, Li H, Wang H, Li Q, Wei X, et al. A thiopyran derivative with low murine toxicity with therapeutic potential on lung cancer acting through a NF-κB mediated apoptosis-to-pyroptosis switch. Apoptosis. 2019;24(1–2):74–82.PubMedCrossRef
121.
Feng J, Li M, Wei Q, Li S, Song S, Hua Z. Unconjugated bilirubin induces pyroptosis in cultured rat cortical astrocytes. J Neuroinflammation. 2018;15(1):23.PubMedPubMedCentralCrossRef
122.
An Q, Fan CH, Xu SM. Recent perspectives of pediatric leukemia: an update. Eur Rev Med Pharmacol Sci. 2017;21(4 Suppl):31–6.PubMed
123.
124.
Metayer C, Milne E, Clavel J, Infante-Rivard C, Petridou E, Taylor M, et al. The childhood leukemia international consortium. Cancer Epidemiol. 2013;37(3):336–47.PubMedPubMedCentralCrossRef
125.
Amitay EL, Keinan-Boker L. Breastfeeding and childhood leukemia incidence: a meta-analysis and systematic review. JAMA Pediatr. 2015;169(6): e151025.PubMedCrossRef
126.
Razmara M, Srinivasula SM, Wang L, Poyet JL, Geddes BJ, DiStefano PS, et al. CARD-8 protein, a new CARD family member that regulates caspase-1 activation and apoptosis. J Biol Chem. 2002;277(16):13952–8.PubMedCrossRef
127.
Johnson DC, Taabazuing CY, Okondo MC, Chui AJ, Rao SD, Brown FC, et al. DPP8/DPP9 inhibitor-induced pyroptosis for treatment of acute myeloid leukemia. Nat Med. 2018;24(8):1151–6.PubMedPubMedCentralCrossRef
128.
Linder A, Bauernfried S, Cheng Y, Albanese M, Jung C, Keppler OT, et al. CARD8 inflammasome activation triggers pyroptosis in human T cells. Embo j. 2020;39(19): e105071.PubMedPubMedCentralCrossRef
129.
Okondo MC, Johnson DC, Sridharan R, Go EB, Chui AJ, Wang MS, et al. DPP8 and DPP9 inhibition induces pro-caspase-1-dependent monocyte and macrophage pyroptosis. Nat Chem Biol. 2017;13(1):46–53.PubMedCrossRef
130.
Murakami T, Ockinger J, Yu J, Byles V, McColl A, Hofer AM, et al. Critical role for calcium mobilization in activation of the NLRP3 inflammasome. Proc Natl Acad Sci U S A. 2012;109(28):11282–7.PubMedPubMedCentralCrossRef
131.
132.
Suzuki-Kakisaka H, Sugimoto J, Tetarbe M, Romani AM, Ramirez Kitchen CM, Bernstein HB. Magnesium sulfate increases intracellular magnesium reducing inflammatory cytokine release in neonates. Am J Reprod Immunol. 2013;70(3):213–20.PubMedCrossRef
133.
Chang YY, Kao MC, Lin JA, Chen TY, Cheng CF, Wong CS, et al. Effects of MgSO(4) on inhibiting Nod-like receptor protein 3 inflammasome involve decreasing intracellular calcium. J Surg Res. 2018;221:257–65.PubMedCrossRef
134.
Schröder NW, Eckert J, Stübs G, Schumann RR. Immune responses induced by spirochetal outer membrane lipoproteins and glycolipids. Immunobiology. 2008;213(3–4):329–40.PubMedCrossRef
135.
Luo X, Zhang X, Gan L, Zhou C, Zhao T, Zeng T, et al. The outer membrane protein Tp92 of treponema pallidum induces human mononuclear cell death and IL-8 secretion. J Cell Mol Med. 2018;22(12):6039–54.PubMedPubMedCentralCrossRef
136.
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531–44.PubMedPubMedCentralCrossRef
137.
138.
Wang C, Liu J, Liu Y. Progress in the treatment of HIV-associated lymphoma when combined with the antiretroviral therapies. Front Oncol. 2021;11: 798008.PubMedCrossRef
139.
140.
Burkhardt B, Zimmermann M, Oschlies I, Niggli F, Mann G, Parwaresch R, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol. 2005;131(1):39–49.PubMedCrossRef
141.
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.PubMedPubMedCentralCrossRef
142.
Qiang L, Yuan J, Shouyin J, Yulin L, Libing J, Jian-An W. Sesamin attenuates lipopolysaccharide-induced acute lung injury by inhibition of TLR4 signaling pathways. Inflammation. 2016;39(1):467–72.PubMedCrossRef
143.
Xu P, Cai F, Liu X, Guo L. Sesamin inhibits lipopolysaccharide-induced proliferation and invasion through the p38-MAPK and NF-κB signaling pathways in prostate cancer cells. Oncol Rep. 2015;33(6):3117–23.PubMedCrossRef
144.
Meng Z, Liu H, Zhang J, Zheng Z, Wang Z, Zhang L, et al. Sesamin promotes apoptosis and pyroptosis via autophagy to enhance antitumour effects on murine T-cell lymphoma. J Pharmacol Sci. 2021;147(3):260–70.PubMedCrossRef
145.
146.
Karin M, Delhase M. The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol. 2000;12(1):85–98.PubMedCrossRef
147.
148.
Lan P, Fan Y, Zhao Y, Lou X, Monsour HP, Zhang X, et al. TNF superfamily receptor OX40 triggers invariant NKT cell pyroptosis and liver injury. J Clin Invest. 2017;127(6):2222–34.PubMedPubMedCentralCrossRef
149.
150.
Jones C, Karajannis MA, Jones DTW, Kieran MW, Monje M, Baker SJ, et al. Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro Oncol. 2017;19(2):153–61.PubMed
151.
Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310(17):1842–50.PubMedCrossRef
152.
Booth TC, Wiegers EC, Warnert EAH, Schmainda KM, Riemer F, Nechifor RE, et al. High-grade glioma treatment response monitoring biomarkers: a position statement on the evidence supporting the use of advanced MRI techniques in the clinic, and the latest bench-to-bedside developments. Part 2: spectroscopy, chemical exchange saturation, multiparametric imaging, and radiomics. Front Oncol. 2021;11:811425.PubMedCrossRef
153.
Perry JR, Laperriere N, O’Callaghan CJ, Brandes AA, Menten J, Phillips C, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017;376(11):1027–37.PubMedCrossRef
154.
Karachi A, Dastmalchi F, Mitchell DA, Rahman M. Temozolomide for immunomodulation in the treatment of glioblastoma. Neuro Oncol. 2018;20(12):1566–72.PubMedPubMedCentralCrossRef
155.
156.
Brennecke J, Hipfner DR, Stark A, Russell RB, Cohen SM. Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in drosophila. Cell. 2003;113(1):25–36.PubMedCrossRef
157.
Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH. An overview of microRNAs: biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019;234(5):5451–65.PubMedCrossRef
158.
Tang SL, Gao YL, Chen XB. MicroRNA-214 targets PCBP2 to suppress the proliferation and growth of glioma cells. Int J Clin Exp Pathol. 2015;8(10):12571–6.PubMedPubMedCentral
159.
Wang S, Jiao B, Geng S, Ma S, Liang Z, Lu S. Combined aberrant expression of microRNA-214 and UBC9 is an independent unfavorable prognostic factor for patients with gliomas. Med Oncol. 2014;31(1):767.PubMedCrossRef
160.
161.
162.
Lee SY, Ju MK, Jeon HM, Jeong EK, Lee YJ, Kim CH, et al. Regulation of tumor progression by programmed necrosis. Oxid Med Cell Longev. 2018;2018:3537471.PubMedPubMedCentralCrossRef
163.
Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol. 2021;18(5):280–96.PubMedCrossRef
164.
Fu L, Jin W, Zhang J, Zhu L, Lu J, Zhen Y, et al. Repurposing non-oncology small-molecule drugs to improve cancer therapy: current situation and future directions. Acta Pharm Sin B. 2022;12(2):532–57.PubMedCrossRef
165.
Versteijne E, de Hingh I, Homs MYV, Intven MPW, Klaase JM, van Santvoort HC, et al. Neoadjuvant treatment for resectable and borderline resectable pancreatic cancer: Chemotherapy or chemoradiotherapy? Front Oncol. 2021;11: 744161.PubMedCrossRef
166.
Rogers C, Fernandes-Alnemri T, Mayes L, Alnemri D, Cingolani G, Alnemri ES. Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death. Nat Commun. 2017;8:14128.PubMedPubMedCentralCrossRef
167.
Kim MS, Chang X, Yamashita K, Nagpal JK, Baek JH, Wu G, et al. Aberrant promoter methylation and tumor suppressive activity of the DFNA5 gene in colorectal carcinoma. Oncogene. 2008;27(25):3624–34.PubMedCrossRef
168.
Yokomizo K, Harada Y, Kijima K, Shinmura K, Sakata M, Sakuraba K, et al. Methylation of the DFNA5 gene is frequently detected in colorectal cancer. Anticancer Res. 2012;32(4):1319–22.PubMed
169.
Wang CJ, Tang L, Shen DW, Wang C, Yuan QY, Gao W, et al. The expression and regulation of DFNA5 in human hepatocellular carcinoma DFNA5 in hepatocellular carcinoma. Mol Biol Rep. 2013;40(12):6525–31.PubMedCrossRef
170.
Akino K, Toyota M, Suzuki H, Imai T, Maruyama R, Kusano M, et al. Identification of DFNA5 as a target of epigenetic inactivation in gastric cancer. Cancer Sci. 2007;98(1):88–95.PubMedCrossRef
171.
Diesch J, Le Pannerer MM, Winkler R, Casquero R, Muhar M, van der Garde M, et al. Inhibition of CBP synergizes with the RNA-dependent mechanisms of azacitidine by limiting protein synthesis. Nat Commun. 2021;12(1):6060.PubMedPubMedCentralCrossRef
172.
Ma J, Ge Z. Comparison between decitabine and azacitidine for patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome: a systematic review and network meta-analysis. Front Pharmacol. 2021;12: 701690.PubMedPubMedCentralCrossRef
173.
Chafouleas JG, Pardue RL, Brinkley BR, Dedman JR, Means AR. Regulation of intracellular levels of calmodulin and tubulin in normal and transformed cells. Proc Natl Acad Sci U S A. 1981;78(2):996–1000.PubMedPubMedCentralCrossRef
174.
Ashour AA, Abdel-Aziz AA, Mansour AM, Alpay SN, Huo L, Ozpolat B. Targeting elongation factor-2 kinase (eEF-2K) induces apoptosis in human pancreatic cancer cells. Apoptosis. 2014;19(1):241–58.PubMedCrossRef
175.
Molina-Crespo Á, Cadete A, Sarrio D, Gámez-Chiachio M, Martinez L, Chao K, et al. Intracellular delivery of an antibody targeting gasdermin-B reduces HER2 breast cancer aggressiveness. Clin Cancer Res. 2019;25(15):4846–58.PubMedCrossRef
176.
Schauder DM, Kim J, Nijhawan RI. Evaluation of the use of capecitabine for the treatment and prevention of actinic keratoses, squamous cell carcinoma, and basal cell carcinoma: a systematic review. JAMA Dermatol. 2020;156(10):1117–24.PubMedCrossRef
177.
Li M, Tang D, Yang T, Qian D, Xu R. Apoptosis triggering, an important way for natural products from herbal medicines to treat pancreatic cancers. Front Pharmacol. 2021;12: 796300.PubMedCrossRef
178.
179.
Kosakowska-Cholody T, Lin J, Srideshikan SM, Scheffer L, Tarasova NI, Acharya JK. HKH40A downregulates GRP78/BiP expression in cancer cells. Cell Death Dis. 2014;5: e1240.PubMedPubMedCentralCrossRef
180.
Crittenden MR, Zebertavage L, Kramer G, Bambina S, Friedman D, Troesch V, et al. Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity. Sci Rep. 2018;8(1):7012.PubMedPubMedCentralCrossRef
181.
Zhao X, Shao C. Radiotherapy-mediated immunomodulation and anti-tumor abscopal effect combining immune checkpoint blockade. Cancers (Basel). 2020;12(10).
182.
Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M, Formenti SC. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology. 2014;3: e28518.PubMedPubMedCentralCrossRef
183.
Vasudevan HN, Yom SS. Combining systemic therapy with radiation: head and neck cancer treatments in an era of targeted agents and immunotherapy. J Natl Compr Canc Netw. 2020;18(7):907–13.PubMedCrossRef
184.
Herrera FG, Irving M, Kandalaft LE, Coukos G. Rational combinations of immunotherapy with radiotherapy in ovarian cancer. Lancet Oncol. 2019;20(8):e417–33.PubMedCrossRef
185.
Ko EC, Raben D, Formenti SC. The integration of radiotherapy with immunotherapy for the treatment of non-small cell lung cancer. Clin Cancer Res. 2018;24(23):5792–806.PubMedCrossRef
186.
Hu B, Jin C, Li HB, Tong J, Ouyang X, Cetinbas NM, et al. The DNA-sensing AIM2 inflammasome controls radiation-induced cell death and tissue injury. Science. 2016;354(6313):765–8.PubMedPubMedCentralCrossRef
187.
Li C, Tian M, Gou Q, Jia YR, Su X. Connexin43 modulates X-ray-induced pyroptosis in human umbilical vein endothelial cells. Biomed Environ Sci. 2019;32(3):177–88.PubMed
188.
Wu D, Han R, Deng S, Liu T, Zhang T, Xie H, et al. Protective effects of flagellin A N/C against radiation-induced NLR pyrin domain containing 3 inflammasome-dependent pyroptosis in intestinal cells. Int J Radiat Oncol Biol Phys. 2018;101(1):107–17.PubMedCrossRef
189.
Liu YG, Chen JK, Zhang ZT, Ma XJ, Chen YC, Du XM, et al. NLRP3 inflammasome activation mediates radiation-induced pyroptosis in bone marrow-derived macrophages. Cell Death Dis. 2017;8(2): e2579.PubMedPubMedCentralCrossRef
190.
Liu T, Wu DM, Zhang F, Zhang T, He M, Zhao YY, et al. miR-142a-3p enhances FlaA N/C protection against radiation-mediated intestinal injury by modulating the IRAK1/NF-kappaB signaling pathway. Int J Radiat Oncol Biol Phys. 2022;112(5):1256–68.PubMedCrossRef
191.
Xiao Y, Zhang T, Ma X, Yang QC, Yang LL, Yang SC, et al. Microenvironment-responsive prodrug-induced pyroptosis boosts cancer immunotherapy. Adv Sci (Weinh). 2021;8(24): e2101840.CrossRef
192.
Yu X, He S. GSDME as an executioner of chemotherapy-induced cell death. Sci China Life Sci. 2017;60(11):1291–4.PubMedCrossRef
193.
Zhang L, Jiang YH, Fan C, Zhang Q, Jiang YH, Li Y, et al. MCC950 attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis. Biomed Pharmacother. 2021;143: 112133.PubMedCrossRef
194.
Wang X, Lian Z, Ge Y, Yu D, Li S, Tan K. TRIM25 rescues against doxorubicin-induced pyroptosis through promoting NLRP1 ubiquitination. Cardiovasc Toxicol. 2021;21(10):859–68.PubMedCrossRef
195.
Zhang JM, Yu RQ, Wu FZ, Qiao L, Wu XR, Fu YJ, et al. BMP-2 alleviates heart failure with type 2 diabetes mellitus and doxorubicin-induced AC16 cell injury by inhibiting NLRP3 inflammasome-mediated pyroptosis. Exp Ther Med. 2021;22(2):897.PubMedPubMedCentralCrossRef
196.
Zhang J, Wu H, Yao X, Zhang D, Zhou Y, Fu B, et al. Pyroptotic macrophages stimulate the SARS-CoV-2-associated cytokine storm. Cell Mol Immunol. 2021;18(5):1305–7.PubMedPubMedCentralCrossRef
197.
Wang Q, Wang Y, Ding J, Wang C, Zhou X, Gao W, et al. A bioorthogonal system reveals antitumour immune function of pyroptosis. Nature. 2020;579(7799):421–6.PubMedCrossRef
198.
199.
Fang Y, Tian S, Pan Y, Li W, Wang Q, Tang Y, et al. Pyroptosis: a new frontier in cancer. Biomed Pharmacother. 2020;121: 109595.PubMedCrossRef
200.
Tan Y, Chen Q, Li X, Zeng Z, Xiong W, Li G, et al. Pyroptosis: a new paradigm of cell death for fighting against cancer. J Exp Clin Cancer Res. 2021;40(1):153.PubMedPubMedCentralCrossRef
201.
Van Laer L, Huizing EH, Verstreken M, van Zuijlen D, Wauters JG, Bossuyt PJ, et al. Nonsyndromic hearing impairment is associated with a mutation in DFNA5. Nat Genet. 1998;20(2):194–7.PubMedCrossRef
202.
Meyran D, Terry RL, Zhu JJ, Haber M, Ziegler DS, Ekert PG, et al. Early-phenotype CAR-T cells for the treatment of pediatric cancers. Ann Oncol. 2021;32(11):1366–80.PubMedCrossRef
203.
Cacciotti C, Choi J, Alexandrescu S, Zimmerman MA, Cooney TM, Chordas C, et al. Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience. J Neurooncol. 2020;149(1):113–22.PubMedCrossRef
204.
MarjaŃska A, Drogosiewicz M, Dembowska-BagiŃska B, PawiŃska-WĄsikowska K, Balwierz W, Bobeff K, et al. Nivolumab for the treatment of advanced pediatric malignancies. Anticancer Res. 2020;40(12):7095–100.PubMedCrossRef
205.
Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–33.PubMedPubMedCentralCrossRef
206.
Metadata
Title
The emerging role of pyroptosis in pediatric cancers: from mechanism to therapy
Authors
Hua Wang
Xiaowen Zhou
Chenbei Li
Shuxiang Yan
Chengyao Feng
Jieyu He
Zhihong Li
Chao Tu
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2022
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-022-01365-6

Other articles of this Issue 1/2022

Journal of Hematology & Oncology 1/2022 Go to the issue

Review

Natural killer cells in clinical development as non-engineered, engineered, and combination therapies

Review

Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?

Review

Emerging role of exosomes in cancer progression and tumor microenvironment remodeling

Letter to the Editor

A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study

Correspondence

Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials

Research

CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits